Clinical Research Directory
Browse clinical research sites, groups, and studies.
Drug Response Testing and Repurposing Using Glioblastoma Organoid
Sponsor: Chungnam National University Hospital
Summary
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Official title: Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2021-08-18
Completion Date
2030-12
Last Updated
2025-01-20
Healthy Volunteers
No
Conditions
Interventions
Organoid-based drug sensitivity test
The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis. The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis.
Locations (1)
Chungnam National University Hospital
Daejeon, Chungcheongnam-do, South Korea